Trials BRAVE AA1 and BRAVE AA2 report Baricitinib to treat Alopecia Areata
Alopecia areatai.e hair loss is a known autoimmune condition affecting the scalp, eyebrows, and eyelashes, for which treatments are limited. Baricitinib, an oral selective is known to cure hair loss.
Nearly 40% of adults with alopecia areata taking baricitinib, an oral Janus kinase (JAK) 1 and 2 inhibitors, see significant hair regrowth over 52 weeks, according to updated results from two phases 3 trials presented at the American Academy of Dermatology 2022 annual meeting.
The results indicated improved response rates and hair growth among trial participants study findings are published in The New England Journal of Medicine. All patients enrolled in the two trials, called BRAVE-AA1 and BRAVE-AA2, had severe alopecia areata, defined as a Severity of Alopecia Tool (SALT) score of ≥ 50, meaning 50% or less scalp coverage.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.